AUS
NZ
UK
CA
USA
IND
Bayer AG (BAYRY), the German pharmaceutical and agricultural giant, reported a significant net loss for the second quarter, falling short of analysts' expectations due to a challenging agricultural market. The company posted a net loss of €34 million ($37.2 million), a substantial improvement from the €1.89 billion loss recorded in the same quarter the previous year. However, this result was significantly below the €70 million net profit anticipated by analysts.
Earnings Breakdown
Earnings before interest, taxes, depreciation, and amortization (EBITDA) before special items—a critical measure of the company’s performance—fell to €2.11 billion from €2.53 billion, though it slightly exceeded analysts' forecasts of €2.08 billion. Bayer's core earnings per share dropped to €0.94 from €1.22, again surpassing the expected €0.84.
Revenue Performance
Despite the earnings decline, Bayer's sales increased to €11.14 billion from €11.04 billion, beating the consensus estimate of €10.82 billion. The growth was driven by a rise in sales across its crop science and pharmaceutical divisions.
Crop Science Division
Sales in the crop science division, adjusted for currency effects, rose by 1.1% to €4.98 billion, primarily driven by strong demand for glyphosate-based herbicides, especially in North America. However, the unfavorable product mix in this segment contributed to the overall net loss.
Bayer has revised its full-year outlook for the crop science division, now expecting sales growth at the lower end of the previously projected range of -1% to +3%. Additionally, the EBITDA margin before special items is anticipated to be at the lower end of the 20%-22% range.
Pharmaceuticals Division
The pharmaceuticals division experienced a 4.5% increase in sales, thanks to the performance of new cancer drug Nubeqa and kidney-disease treatment Kerendia. These gains offset the declining revenue from Bayer's leading blood-thinning drug Xarelto, which faced stiff competition from generic alternatives.
For the pharmaceuticals division, Bayer has adjusted its sales growth forecast to between 0% and 3%, a narrower range compared to the previous guidance of -4% to 0%.
Market Reaction and Future Outlook
Bayer's second-quarter results highlight the ongoing challenges in the agricultural sector, which continue to impact the company's financial performance. Despite the net loss, the company managed to exceed some key expectations, suggesting resilience in its core operations. Bayer reiterated its overall group guidance for the year, signaling confidence in its ability to navigate these challenges.
